Green Alpha Advisors’s SOPHiA GENETICS SOPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$247K Sell
42,765
-187
-0.4% -$949 0.17% 93
2026
Q1
$213K Sell
42,952
-2,708
-6% -$13.2K 0.21% 93
2025
Q4
$213K Buy
45,660
+4,444
+11% +$20.1K 0.2% 101
2025
Q3
$196K Sell
41,216
-1,690
-4% -$5.81K 0.19% 91
2025
Q2
$133K Sell
42,906
-4,172
-9% -$12.4K 0.13% 99
2025
Q1
$156K Sell
47,078
-138
-0.3% -$485 0.17% 98
2024
Q4
$145K Buy
47,216
+25,686
+119% +$87.4K 0.12% 134
2024
Q3
$78.6K Buy
+21,530
New +$87.5K 0.06% 137

Other funds holding SOPH

Green Alpha Advisors's SOPH Position: Q2 2026 in Review

Green Alpha Advisors reduced its SOPHiA GENETICS (SOPH) stake by 0.44% in Q2 2026, selling an estimated $949 and leaving 42,765 shares worth $247K. The position accounts for 0.17% of the portfolio, ranked #93.

Green Alpha Advisors first reported a position in SOPH in Q3 2024 and has held it in 8 quarters since. 72 funds tracked by Wall St. Rank hold SOPH as of Q2 2026.

  • Green Alpha Advisors held 42,765 shares of SOPHiA GENETICS worth $247K as of Q2 2026.
  • Green Alpha Advisors sold 187 SOPHiA GENETICS shares in Q2 2026, an estimated $949.
  • SOPHiA GENETICS made up 0.17% of Green Alpha Advisors's portfolio in Q2 2026, its #93 holding.
  • Green Alpha Advisors first reported a position in SOPHiA GENETICS in Q3 2024 and has held it in 8 quarters since.
  • 72 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q2 2026.

Based on Green Alpha Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.